No Data
No Data
Cartesian Therapeutics Cash, Cash Equivalents, And Restricted Cash Of $88.9M And Net Proceeds From $130M Pipe Financing Are Expected To Support Development Of Descartes-08 In Myasthenia Gravis; End-of-phase 2 Meeting With FDA Expected By Year-end
Cartesian Therapeutics Q2 2024 GAAP EPS $0.54 May Not Be Comparable To $(1.19) Estimate, Sales $33.445M May Not Be Comparable To $1.200M Estimate
Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates
Cartesian Therapeutics | 10-Q: Quarterly report
Earnings Flash (RNAC) CARTESIAN THERAPEUTICS Reports Q2 Revenue $33.4M
Cartesian Therapeutics 2Q Rev $33.4M >RNAC